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Circulating Progenitor Cells,
Angiogenesis, and Reverse Cholesterol Transport
Pedro R. Moreno, MD,* Javier Sanz, MD,* Valentin Fuster, MD, PHD,*†
New York, New York; and Madrid, Spain
To understand and promote vascular health, we must reduce the aggression to the vessel wall and enhance the
physiologic mechanisms leading to restoration of vessel wall function. Three main defense mechanisms are re-
sponsible for maintaining cardiovascular homeostasis: the regenerative production of endothelial progenitor
cells, vessel wall angiogenesis, and macrophage-mediated reverse cholesterol transport. Endothelial progenitor
cells can restore vessel wall function and reduce atherosclerosis. In patients with risk factors, high levels of cir-
culating progenitor cells increase event-free survival from cardiovascular events. Mobilization of progenitor cells
includes physical and pharmacological approaches, of which exercise and statin therapy have great potential.
Angiogenesis is a pivotal defense mechanism to counteract hypoxia and is needed for plaque regression. How-
ever, neovessels are susceptible for intraplaque hemorrhage, particularly in diabetes mellitus. In these patients,
the haptoglobin 2-2 genotype is the more affected, and may benefit from an antioxidant approach. Finally, the
reverse cholesterol transport system is the main mechanism for plaque regression. In addition to high-density
lipoprotein cholesterol, apolipoprotein A-I therapies and the promotion of cholesterol efflux from macrophages
by the ABCA1 and ABCG1 transporter systems hold great promise and may be available for therapeutic applica-
tion in the near future. (J Am Coll Cardiol 2009;53:2315–23) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.057s
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pndependent of sex, race, or income, cardiovascular disease
CVD) is by far the leading cause of death in the world,
ith an unsustainable economic burden for our society (1).
s a result, our health system needs to be revised to reduce
ost and promote health. This implies a major shift of
entality: from disease treatment to promotion of health.
t the vascular level, this can be achieved by reducing vessel
all injury and promoting physiologic repair. Vessel wall
omeostasis is a fine balance between injury and the defense
echanisms of repair. This review will address these defense
echanisms to promote health, with special focus on the
oronary arteries.
Atherosclerosis evolves from subendothelial retention of
ipoproteins through the leaky and defective endothelium,
here these plasma molecules are modified (e.g., oxidized) and
ecome cytotoxic, proinflammatory, chemotaxic, and
roatherogenic (2). The response-to-injury hypothesis consid-
rs inflammation as a central mechanism responsible for early
therogenesis (3–8). Arterial wall injury, mostly mediated by
ging, diabetes, smoking, hypercholesterolemia, and hyperten-
rom the *Zena and Michael A. Wiener Cardiovascular Institute, and the Marie-
osee and Henry R. Kravis Cardiovascular Health Center, The Mount Sinai School
f Medicine, New York, New York; and †The Centro Nacional de Investigaciones
ardiovasculares (CNIC), Madrid, Spain.P
Manuscript received November 14, 2008; revised manuscript received January 27,
009, accepted February 6, 2009.ion, triggers an inflammatory response, a defense mechanism
o restore arterial wall integrity. However, persistence of risk
actor–mediated arterial wall injury leads to endothelial dys-
unction, atheromatous plaque formation (9), plaque rupture,
nd thrombotic complications, the overall process of athero-
hrombosis (10,11). Simultaneously, inflammation also orches-
rates a process of repair through 3 main defense mechanisms,
llustrated in Figure 1. These include: 1) endothelial repair by
rogenitor cells; 2) plaque neovascularization; and 3) reverse
holesterol transport.
ndothelial Repair by Progenitor Cells
ndothelial dysfunction finally leads to endothelial cell
eath, lipid entry, invasion of inflammatory cells, and
ascular smooth muscle cell proliferation. An initial func-
ional impairment of the endothelial monolayer with a high
hance of reversibility now turns into structural damage
12). However, regeneration can occur. In 1997, Asahara
t al. (13) identified bone marrow–derived circulating en-
othelial progenitor cells (EPCs) from the bloodstream and
stablished their regenerative potential. EPCs are a sub-
roup of peripheral blood monocytes that express stem
ell–like antigenic determinants including CD34 and the
ascular endothelial growth factor 2 receptor (14). Other
rogenitor markers, including CD31, CD133, CD117,
1H12, cKit, Sca1, and CXCR4, may also be relevant
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ated by the activation of chemo-
kines and perhaps activated plate-
lets, provides the signals for
dynamic trafficking of EPCs
(14,15). Several studies have in-
vestigated the mechanistic pro-
tective role of EPCs in experi-
mental animal models (16), with
recent inhibition of plaque for-
mation by local administration of
EPCs in a rabbit model (17). We
will now review the role of EPCs
in predicting CVD in patients
with risk factors.
EPC consumption, cardiovascu-
lar risk factors, and disease. The
umber of circulating and colony-forming units of EPCs is
ssociated with a lower risk score in men without history of
VD (18). A competent bone marrow can translate injury
nto productive EPC consumption and recruitment, re-
toring endothelial function. However, a high risk factor
rofile perpetuates injury, the bone marrow becomes
ncompetent, and so the EPCs number in the process of
epair (19).
PC function in subclinical CVD. Several studies have
valuated the relationship between EPCs and the presence
f subclinical atherosclerosis. In the elderly, reduced flow-
ediated brachial artery reactivity correlates with dysfunc-
ional EPCs (20). The number of circulating EPCs is 44%
ower in diabetes mellitus, correlating with high levels of
emoglobin (Hb) A1c (21) and the severity of diabetic
rteriopathy in different vascular territories. Thus, in dia-
etic patients with carotid disease, the lowest levels of EPCs
Abbreviations
and Acronyms
ApoA-I  apolipoprotein A-I
CETP  cholesterol ester
transporter protein
CVD  cardiovascular
disease
EPC  endothelial
progenitor cell
Hb  hemoglobin
HDL  high-density
lipoprotein
HDL-C  high-density
lipoprotein cholesterol
Hp  haptoglobin
Figure 1 Mechanisms of Vascular Health
Defense mechanisms responsible for maintaining endothelial and vessel wall hom
vascularization; and 3) reverse cholesterol transport and plaque regression. LDL 
fied, with permission, from Fuster et al. (10).re observed in patients with carotid stenosis 70% (22).
PC levels directly correlated with the ankle-brachial index,
ith extremely low levels observed in patients with athero-
clerosis obliterans (22). Furthermore, diabetic patients with
oronary artery disease show a further reduction in the
umber of circulating EPCs (23). Most importantly, in-
reased concentration and function of EPCs decrease the
ikelihood of severe coronary disease. For every 10-colony
orming unit increase in EPCs, a patient’s likelihood for
ultivessel coronary disease declined by 20% (23).
PCs and cardiovascular events. The number of circulat-
ng EPCs was associated with a reduced risk for cardiac
eath and all other coronary events, as shown in Figure 2
24). This and other studies suggest that decreased levels of
irculating EPCs are seen in patients with coronary risk
actors and reflect senescence, endothelial dysfunction, im-
aired vascular repair, and increased cardiovascular events.
odulating EPCs: implications for therapy. Enhance-
ent of EPCs is considered one of the most promising
herapeutic alternatives for cardiovascular disease (25). The
rocess of EPC mobilization leads to accelerated re-
ndothelialization, successfully achieved by erythropoietin
nd other growth factors (26,27). Physical exercise increases
itric oxide availability, improving EPC regeneration (28).
everal pharmacological pathways may mobilize and in-
rease EPCs, and statin therapy is the most studied so far
29–33). Although statins may have a direct stimulating
ffect on EPC synthesis and release into the circulation, the
ipid-lowering and anti-inflammatory effects will reduce
ggression to the vascular wall. All together will eventually
itigate inflammation and finally passivate the system (34).
ther potential pharmacological approaches to enhance
PCs include the peroxisome proliferator-activated recep-
or agonists, and medications involved in the renin-
is, including: 1) endothelial progenitor cells; 2) angiogenesis and plaque neo-
ensity lipoprotein; MMP  matrix metalloproteinase; TF  tissue factor. Modi-eostas
low-d
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June 23, 2009:2315–23 Promoting Biological Pathways for Vascular Healthngiotensin system (35–38). A better understanding of how
PCs generate and interact with each other (39–41), as
ell as the identification of specific functions through
maging technology (42,43), may significantly contribute to
he enhancement of such defense mechanisms (44).
ngiogenesis and Plaque Neovascularization
eovascularization is a pivotal defense mechanism to main-
ain homeostasis and restore healthy tissue in wound heal-
ng, myocardial necrosis, chronic ischemia, and regeneration
f heart muscle by stem cell therapy (45). In the normal
essel wall, oxygen is provided to the tunica intima by direct
iffusion from the lumen, whereas the tunic media and the
dventitia are nurtured by vasa vasorum, maintaining met-
bolic homeostasis and removing waste products. When an
therosclerotic lesion evolves in the intima, the intima
ecomes thicker, and the distance between the deep layers
f the intima and the luminal surface increases and ulti-
ately exceeds the oxygen diffusion threshold (250 to 500
m), resulting in local hypoxia and induction of neovascu-
arization. Indeed, in rabbit aortic plaques thicker than 500
m, the majority of viable macrophages present in the lipid
ore were severely hypoxic, glucose-depleted, and adenosine
riphosphate–depleted, a condition likely leading to macro-
Figure 2 Improved Survival in Patients With High
Levels of Circulating Endothelial Progenitor Cells
Cumulative event-free survival in an analysis of death from cardiovascular
causes at 12 months according to levels of circulating CD34 KDR endothe-
lial progenitor cells at the time of enrollment. Reprinted, with permission, from
Werner et al. (24).hage death and formation of a necrotic lipid core (46). As tresult, plaque neovascularization, either from pre-existing
ndothelial cells (angiogenesis [45]) or from bone marrow–
erived EPCs (vasculogenesis [47]), is an essential defense
echanism to compensate hypoxia and restore homeostasis
n the vessel wall (48,49).
Major insights from the role of neovessels in atheroscle-
osis originally evolved from progression and regression
xperimental studies in primates (50). Disease progression is
ssociated with a 10-fold increase in vessel wall flow
hrough vasa vasorum, a defense mechanism response for
he removal of waste products (51). As soon as the stimuli
or progression stopped, flow through vasa vasorum started
o diminish, coming back to baseline levels. Lipid content
as reduced along with very low levels of inflammatory
ells, leading to plaque regression (51,52). As a result,
eovessels serve as a pathway for macrophages to get out of
ipid-rich plaques and stabilize atherosclerotic plaques (52).
Despite all of these beneficial effects, plaque neovascular-
zation is associated with inflammation and may paradoxi-
ally contribute to plaque rupture (53). Hence, an important
uestion needs to be addressed. How does a defense
echanism fail and trigger complex disease? The answer
ppears to be intraplaque hemorrhage. Plaque neovessels are
ragile structures, with single-layer endothelial cells prone to
eakage and/or rupture, allowing for extravasation of red
lood cells (RBCs) (48). Erythrocyte membranes are very
ich in cholesterol, contributing to lipid expansion (54). In
ddition, RBC lysis releases free Hb, generating reactive
xygen species (ROS) and increasing lipid peroxidation and
acrophage activation within the atherosclerotic plaque.
ntraplaque hemorrhage, haptoglobin, and macrophage
nteraction in plaque stability. The heme iron compo-
ent of Hb generates ROS and activates the proinflam-
atory nuclear transcription factor-B (55), leading to
nflammation. The haptoglobin (Hp) pathway promotes
learance of free Hb through the Hp-Hb complex. This
learance is finally scavenged by the macrophage receptor
D163 (56). Thus, the ability of the macrophage to
liminate the Hp-Hb complex may influence plaque
tability. However, the Hp genotype has been shown to
lay a role in disease progression (57). Two classes of
lleles (Hp-1 and Hp-2) synthesize proteins that are
tructurally and functionally distinct. Functionally, the
p-1 allele protein product is superior to the Hp-2 allele
rotein. Multiple epidemiological studies have demon-
trated that diabetic individuals with the Hp 2-2 geno-
ype (homozygous for the Hp-2 allele) are at 4 to 5 times
reater risk of cardiovascular events (58 – 61). This is
elated to a reduced clearance of macrophage-Hp-Hb
omplex, favoring iron deposition, oxidative stress, and
ctive macrophage accumulation (62– 64). Furthermore,
iabetic patients with the Hp 2-2 genotype exhibit a
evere down-regulation of the macrophage scavenger
eceptor CD163 (65). It has been suggested that such
verall accumulation of activated macrophages failing to
arget Hb clearance may contribute, by matrix metallo-
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Promoting Biological Pathways for Vascular Health June 23, 2009:2315–23roteinase expression, to the digestion of the internal
lastic lamina, and so to plaque disruption, as seen in
igure 3 (66).
odulating deleterious effects of Hb genotype and
laque neovascularization: implications for protective
herapy. Increased oxidative stress in diabetic individuals
ith the Hp 2-2 genotype may be antagonized by the use
f antioxidant therapy. Although vitamin E does not
revent cardiovascular events in the overall population, a
ubgroup analysis of diabetic individuals with the Hp 2-2
enotype in the Heart Outcomes Prevention Evaluation
tudy suggested a reduction in the primary composite
vents (67). Recent prospective studies are encouraging
68 –70), but clearly require more extensive documenta-
ion before being considered for clinical application. Of
nterest, the Hp-Hb complex binds to apolipoprotein
Apo) A-I, inducing oxidation and leading to dysfunction
f high-density lipoprotein (HDL) (71), as seen in Figure
. Vitamin E decreased oxidative modification of HDL,
mproving HDL function in diabetic patients with the
p 2-2 genotype (71).
Regarding potential therapies for modulation of plaque
eovascularization, statin therapy has shown plaque re-
ression in experimental animals (72,73) and most re-
ently in humans by means of magnetic resonance imag-
ng (74,75). Presumably, statins establish a concentration
radient tissue/blood of low-density lipoprotein choles-
erol (LDL-C), thus favoring its removal from tissue and
ubsequent regression of the neovessels. However, mod-
Figure 3 Hp Genotype, Inflammation, and Plaque Destabilizatio
The haptoglobin (Hp)-1 and -2 genotypes play opposite roles in macrophage functi
hemoglobin (Hb)–Hp-1 complex is generated that binds to the macrophage CD163
(IL-10). Conversely, after plaque hemorrhage in individuals with the Hp-2 genotype
(ROS) and induces macrophages to secrete proinflammatory cytokines by both CD
tor. Reprinted, with permission, from Moreno et al. (48).lating neovessel growth is subject to controversy. Proan-
iogenic therapy to promote the above mentioned de-
ense mechanism might lead to neovessel growth in
ncogenic regions. On the other hand, antiangiogenic
herapy to prevent erythrocyte-macrophage active accu-
ulation may have clinical detrimental effects (76 –78).
s a result, pharmacological or immunological modula-
ion of angiogenesis still faces difficult obstacles before
pplication for clinical therapy (79).
everse Cholesterol Transport
he third presumed defense mechanism to preserve vessel
all integrity is known as reverse cholesterol transport.
ntroduced by Glomset (80) in 1968, the term describes a
rocess by which extrahepatic (peripheral) cholesterol re-
urns to the liver for excretion in the bile and feces.
nesterified (free) cholesterol is toxic to cells, and on the
asis of this concept, Ross and Glomset (81) proposed that
therosclerosis is the result of an imbalance between depo-
ition and removal of arterial cholesterol after endothelial
njury. This theory was further strengthened by the inverse
elationship between high-density lipoprotein cholesterol
HDL-C) and cardiovascular disease. Increasing the
DL-C level by 1 mg/dl may reduce the risk of cardiovas-
ular disease by 2% to 3%. This is consistent with the
oncept of a beneficial role of HDL-C, which is based on
ree cholesterol efflux from macrophages out of the vessel
all. This efflux occurs either by passive diffusion (82) or by
r plaque hemorrhage. In individuals with the Hp-1 genotype, a redox-inactive,
tor to induce the secretion of anti-inflammatory cytokines such as interleukin-10
ox-active Hb–Hp-2 complex is generated that produces reactive oxygen species
pendent and -independent pathways, as shown. NF  nuclear transcription fac-n
on afte
recep
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June 23, 2009:2315–23 Promoting Biological Pathways for Vascular Healthnteraction with the SR-BI receptor (83) or the ABCA1
ransporter (84), as shown in Figure 5. Of these, the
BCA1 transporter system is the most efficient, responsible
or over 50% of cholesterol efflux from macrophages to
oorly lipidated ApoA-I. This pivotal protein is then
onverted to mature alpha-HDL after esterification. Mature
DL-C also transfers esterified cholesterol to other li-
oproteins by the enzyme cholesterol ester transporter
rotein (CETP), increasing the efficiency of the system
85). There is also evidence that HDL-C also reduces
DL-C oxidation, and endothelial cell adhesion expression
86). In addition, HDL-C improves re-endothelialization
hrough EPC activation and proliferation (87). Further-
ore, the antiatherosclerotic role of anti-inflammatory cy-
okines such as interleukin-10 may be associated with
DL-C reverse cholesterol transport. As a result, increas-
ng HDL-C may participate in several pathways to prevent
VD.
xperimental and clinical studies on HDL-C protective
herapy. The first study demonstrating atherosclerotic
laque regression with exogenous administration of HDL
as performed by Badimon et al. (88) in hypercholester-
lemic rabbits with significant reductions in both esterified
nd free cholesterol in aortic plaques. Several other studies
onfirmed these beneficial effects of HDL-C, mostly with
he direct infusion and/or overexpression of HDL’s major
Figure 4 Haptoglobin Genotype and HDL Function
Hemoglobin (Hb) released intravascularly from red blood cells (RBCs) is rapidly bo
als, the complex is cleared by the scavenger receptor CD163 more slowly than in
high-density lipoprotein (HDL), with increased binding of Hp 2-2-Hb occurring due t
but not the Hp 1-1–Hb complex, when bound to HDL can produce reactive oxygen
lesterol acyltransferase [LCAT]) and lipid components (cholesterol [chol]) of HDL a
[RCT] and antioxidant activity), proatherogenic, and prothrombotic. DM  diabetesrotein, ApoA-I (89–92). A second group of studies sup-
orting the concept that increasing HDL-C reduces ath-
rosclerosis relates to the CETP enzyme pathway. From an
xperimental point of view, the data on CETP expression
ave been controversial. In some studies, overexpression of
ETP reduced atherosclerosis (93), whereas in others,
therosclerosis is actually increased (94,95). Studies in
umans with CETP deficiency are also controversial. In
ome studies, CETP deficiency has been atherogenic
96,97), whereas in others, it has not (98,99). The hypoth-
sis that HDL-C could be increased via CETP inhibition
as tested in 15,000 patients randomized to torcetrapib plus
torvastatin versus atorvastatin alone. Results prove to be
etrimental, with increases in death, heart failure, angina,
nd revascularization procedures in the combined torce-
rapib plus atorvastatin group when compared to the ator-
astatin group (100). The question is whether other agents
ith different interactions with CETP will provide favor-
ble results. Torcetrapib was associated with activation in
he renin-angiotensin-aldosterone system, perhaps in part
xplaining the increased risk of death in the trial. Intravas-
ular ultrasound studies showed no changes in atheroma
olume (101).
linical studies on niacin and on CETP deficiency or
nhibition. Niacin has been the most consistent medication
o increase HDL-C, leading to significant reductions in
haptoglobin (Hp) protein to form an Hp-Hb complex. In Hp 2-2 diabetic individu-
diabetic individuals. The Hp-Hb complex can bind to apolipoprotein (Apo)A-I in
creased avidity for HDL and its increased plasma concentration. The Hp 2-2–Hb,
s, which can oxidize protein (i.e., ApoA-I; GPx-glutatione peroxidase; lecithin cho-
der the HDL dysfunctional (due to decreased reversed cholesterol transport
us. Reprinted, with permission, from Asleh et al. (71).und by
Hp 1-1
o its in
specie
nd ren
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Promoting Biological Pathways for Vascular Health June 23, 2009:2315–23yocardial infarction and cardiac death (102). Niacin fa-
orably affects apolipoprotein containing lipoproteins, in-
reasing HDL’s major protein, ApoA-I (103). As mono-
herapy, niacin was tested in the Coronary Drug Project,
hich included 3,908 patients with previous myocardial
nfarction. This study reported a 27% decrease in nonfatal
nfarction and a 12% reduction in cardiac death at 15-year
ollow-up (104). In addition, the Stockholm Ischaemic
eart Disease Secondary Prevention Study included 900
atients with recent infarction, and combined immediate-
elease niacin 3.0 g/day with clofibrate 2 g/day (105). This
tudy reported a 35% reduction in cardiac death at 4-year
ollow-up. The question is whether neutralization of the
iacin molecule implicated in the frequent side effects of
ushing can be obtained without causing other side effects.
uch an agent (Cordaptive, Merck, Whitehouse Station,
ew Jersey) was recently reviewed by the Food and Drug
dministration, which requested further studies before
onsideration for approval (106).
uture alternatives for reverse cholesterol transport and
laque regression. Two potential pathways are being ac-
ively investigated for clinical implementation. These are the
BCA1 transporter and the ApoA-I system (107). Exper-
mental overexpression of ABCA1 transporter protein is
Figure 5 Mechanisms of Reverse Cholesterol Transport
There are 3 major pathways by which HDL may mediate cholesterol efflux from cho
exchange of free cholesterol (FC) between mature spherical -HDL and the cellular
ester (CE) by LCAT. In the SR-BI pathway, free cholesterol is transported to mature
transporter pathway, the preferred acceptor of cellular cholesterol is poorly lipidate
cholesterol from the late endocytic compartment, thereby decreasing the choleste
phages and other peripheral tissues results in the formation of pre-HDL, which is
LCAT. (Right) Both the SR-BI and ABCA1 transporter pathways are regulated by th
part, to 27-hydroxycholesterol by 27-hydroxylase. The 27-hydroxycholesterol binds
binds to the LXRE promoter element and increases the expression of SR-BI and th
cellular cholesterol and participate in reverse cholesterol transport to the liver. Abssociated with a significant regression of atherosclerosis in pice (108). Both ABCA1 and ABCG1 are regulated by
iver X receptor (109), and synthetic agonists of this nuclear
eceptor promote reverse cholesterol transport in vivo (110).
ndeed, administration of such agonists has been associated
ith reduced atherosclerosis in mice (111).
The second potential pathway for clinical implementa-
ion is the repeated infusion/overexpression of ApoA-I,
ith documented regression of atherosclerosis in animal
odels and humans (112). Infusion of ApoA-I also shifts
laque activity to a more stable phenotype (113). One of the
ore interesting of these approaches is the concept of
poA-I mimetic peptides, which mimic the antiathroscle-
otic and anti-inflammatory properties of full-length
poA-I (114). However, most peptides are not orally
ioavailable and must be administered parenterally. At least
intravenously administered ApoA-I mimetic peptide,
nown as the RLT peptide (ETC-642, Esperion Thera-
eutics Inc., Ann Arbor, Michigan), is being studied in
linical trials. Another ApoA-I mimetic peptide is D-4F, an
8-amino acid peptide not degraded efficiently by gut
eptidases and that can, therefore, be administered orally,
lbeit with low bioavailability (114). D-4F reduced athero-
clerosis in mice (115), probably at least partly by increasing
he anti-inflammatory effects of HDL-C, as well as by
ol-loaded macrophages (left). The first pathway, passive diffusion, involves
brane. Net cholesterol efflux occurs after the conversion of FC to cholesterol
rical -HDL. The third pathway involves the ABCA1 transporter. In the ABCA1
A-I, which binds to the ABCA1 transporter and facilitates the efflux of cellular
tent of the cell. The efflux of cholesterol and phospholipids (PL) from macro-
ately converted to mature spherical -HDL after the esterification of FC to CE by
holesterol content of the cell. Excess cellular cholesterol is converted, at least in
ligand-stimulated transcription factor LXR, which, after dimerization with RXR,
A1 transporter genes. Thus, both mature and pre-HDL facilitate the efflux of
ions as in Figure 4. Reprinted, with permission, from Brewer et al. (85).lester
mem
sphe
d Apo
rol con
ultim
e oxyc
to the
e ABC
breviatromoting macrophage reverse cholesterol transport (116).
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June 23, 2009:2315–23 Promoting Biological Pathways for Vascular Healths a result, D-4F may improve HDL-C function, and
uman trials are ongoing with the aim of reducing cardio-
ascular risk without increasing plasma HDL-C levels.
Although infusions of HDL-C and oral ApoA-I mimetic
eptides may contribute to plaque regression, this therapeu-
ic option clearly requires more extensive documentation
efore being considered for clinical application.
onclusions
hree main defense mechanisms are responsible for main-
aining cardiovascular homeostasis: the regenerative produc-
ion of EPCs, plaque neovascularization, and the reverse
holesterol transport system. EPCs can reverse endothelial
ysfunction and prevent atherosclerosis in animal models.
n humans with risk factors, low levels of circulating EPCs
re associated with reduced event-free survival. Diabetic
atients with coronary and peripheral vascular disease ex-
ibit the lowest levels of EPCs. Mobilization of EPCs can
e achieved with physical exercise and statin therapy.
egarding plaque angiogenesis, it is now established that
eovessels are a pivotal defense mechanism against vessel
all hypoxia. However, they may fail and allow extravasa-
ion of erythrocytes leading to intraplaque hemorrhage. In
iabetic patients, the haptoglobin 2-2 genotype is the more
ffected, and may benefit from an antioxidant approach.
inally, the reverse cholesterol transport system will have a
ery active role as a therapeutic pathway in the very near
uture. ApoA-1 therapies and the promotion of cholesterol
fflux from macrophages by the ABCA1 and ABCG1
ransporter systems hold great promise as therapeutic ap-
roaches in the fight against cardiovascular disease.
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